Opinion
Volume 12:05, 2024

Journal of Clinical & Medical Genomics

ISSN: 2472-128X

Open Access

The Promise and Perils of Direct-to-Consumer Genetic Testing in Clinical Practice

Akkari Anthena*

Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano, (TO), Italy

Introduction

In recent years, Direct-To-Consumer (DTC) genetic testing has garnered significant attention, offering individuals the ability to access their genetic information without the need for a healthcare provider's involvement. Companies such as 23andMe, Ancestry DNA, and others have popularized this concept, allowing consumers to gain insights into their ancestry, genetic predispositions to health conditions, and traits. While DTC genetic testing holds tremendous promise, it also presents a range of challenges that can complicate its integration into clinical practice.

As more consumers turn to genetic testing services to explore their genetic makeup, the healthcare industry faces increasing pressure to address the implications of these tests for clinical care. The accuracy, interpretation, and potential medical uses of genetic data obtained outside a professional healthcare setting are key concerns that must be carefully considered. This article examines the promise and perils of DTC genetic testing in clinical practice, exploring its potential benefits, risks, and the need for proper regulation and professional oversight [1].

Description

DTC genetic testing has made genetic information more accessible and affordable than ever before. Traditionally, genetic testing required a visit to a healthcare provider, who would assess a person's medical history and symptoms before recommending appropriate tests. With DTC testing, the process is simplified: individuals can order a test online, collect a sample (usually saliva), and send it to the company for analysis. Within weeks, they receive reports on a variety of genetic markers related to ancestry, health, traits, and more. DTC genetic tests can offer insights into a person's risk for various diseases, including genetic predispositions for conditions such as Alzheimer's disease, breast cancer, and certain heart conditions. Armed with this information, individuals may take steps toward early prevention or lifestyle adjustments, such as diet changes, exercise routines, or more frequent screenings. Many consumers are drawn to DTC testing for its ability to provide ancestry reports and information on traits such as lactose intolerance, eye color, and muscle composition. While this information may not directly impact clinical care, it can help individuals better understand their genetic inheritance and family history [2].

By providing easy access to genetic data, DTC testing empowers individuals to take a more active role in their health. This sense of autonomy could motivate individuals to pursue a healthier lifestyle, seek genetic counseling, or initiate conversations with healthcare providers about their genetic risks. One of the most exciting possibilities of DTC genetic testing is its potential to identify individuals at higher risk for genetic conditions before symptoms appear. Early identification of risks could allow for preventive measures to be taken, such as adopting a healthier lifestyle, undergoing regular screenings, or even pursuing targeted therapies as part of a personalized treatment plan. Despite its potential benefits, DTC genetic testing also comes with significant risks and challenges. Many of these concerns stem from the lack of regulation, professional oversight, and the complexity of interpreting genetic information without guidance from a healthcare professional.

DTC genetic tests are typically based on analyses of a subset of genetic variants, rather than a comprehensive examination of an individual's entire genome. This means that these tests may miss important mutations or provide incomplete or misleading results. For example, many DTC companies provide information on common genetic variants associated with diseases, but they may not have access to the full range of mutations that could increase a person's risk. Additionally, variations in genes related to health outcomes may not necessarily cause disease, and results may be based on associations that are not fully understood, leading to unnecessary anxiety or a false sense of security. Unlike clinical genetic tests that are subject to rigorous validation processes and oversight by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), many DTC genetic tests are not held to the same standards. This lack of validation can lead to unreliable results, which, when used for medical decision-making, could have detrimental effects. For example, a false positive result for a genetic risk of cancer may cause unnecessary psychological distress and lead to unnecessary medical procedures or screenings.

Genetic information is complex, and without proper counseling or medical guidance, it can be easily misinterpreted. Consumers who are not familiar with genetic science may struggle to understand what the results truly mean for their health, and they might make decisions based on incomplete or incorrect interpretations [3]. For example, knowing that one has a genetic risk for a particular condition might not necessarily indicate that they will develop the condition, nor does it always suggest that there are actionable steps they can take to mitigate the risk. One of the major risks of DTC genetic testing is the absence of professional oversight. While individuals may receive genetic information, there is typically no healthcare professional involved in guiding them through the interpretation or implications of the results. Genetic counselors and physicians play an essential role in helping individuals understand how their genetic information fits into their overall health and medical history. Without these professionals, consumers may not receive the support necessary to make informed decisions or take appropriate actions based on their results.

The collection and storage of genetic data by DTC companies raises important privacy and ethical concerns. Genetic data is deeply personal and can provide a wealth of information about an individual's health, traits, and potential future diseases. Many companies retain users' genetic data and may share it with third parties for research or other purposes, raising questions about consent, confidentiality, and data security. There is also the potential for discrimination based on genetic information, particularly in areas like employment or insurance, despite legal protections like the Genetic Information Nondiscrimination Act (GINA) in the U.S. DTC genetic tests may lead individuals to over-rely on the information they receive from these services, bypassing traditional medical care and genetic counseling. Some individuals may attempt to self-diagnose, ignore symptoms, or delay seeking professional medical advice based on the results of their genetic test. Additionally, they may use DTC genetic testing as a substitute for comprehensive clinical evaluation, potentially missing critical aspects of their health that could be addressed through standard medical care [4].

***Address for Correspondence:** Akkari Anthena, Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano, (TO), Italy; E-mail: anthena.akkari@gmail.com*

Received: 01 October, 2024, Manuscript No. JCMG-24-155584; **Editor assigned:** 03 October, 2024, Pre QC No. P-155584; **Reviewed:** 17 October, 2024, QC No. Q-155584; **Revised:** 23 October, 2024, Manuscript No. R-155584; **Published:** 30 October, 2024, DOI: 10.37421/2472-128X.2024.12.301

The growing popularity of DTC genetic testing has prompted calls for greater regulation to ensure the accuracy, reliability, and ethical use of genetic information. As it stands, DTC tests are often marketed directly to consumers with limited oversight from health authorities. However, recent regulatory efforts have sought to address this gap. For example, the FDA has become more involved in regulating certain DTC tests, especially those that offer health-related information, such as risk assessments for genetic disorders. Ethical challenges also surround the use of genetic testing in clinical practice. Healthcare providers must carefully consider whether to recommend DTC testing to patients and how to integrate the results into their clinical decision-making processes. Ethical considerations include respecting patient autonomy, ensuring informed consent, protecting privacy, and addressing the potential for discrimination based on genetic information [5].

Conclusion

Direct-to-consumer genetic testing holds significant promise for transforming healthcare by providing individuals with access to valuable genetic information. It empowers consumers to take a proactive role in their health, make informed decisions about lifestyle changes, and understand their genetic predispositions to various conditions. However, the integration of DTC genetic testing into clinical practice also presents several challenges and risks, including inaccurate or incomplete information, misinterpretation of results, and the absence of professional guidance.

To maximize the benefits of DTC genetic testing and minimize its potential harms, greater regulation and oversight are necessary. Healthcare providers must also play an active role in guiding patients through the complexities of genetic information and ensuring that the results of DTC tests are interpreted within the appropriate clinical context. As the field of genetics continues to evolve, it is essential that both consumers and healthcare professionals approach DTC genetic testing with a clear understanding of its potential and its limitations, ensuring that genetic data is used responsibly and ethically in the pursuit of personalized healthcare.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Kullo, Iftikhar J., Cathryn M. Lewis, Michael Inouye and Alicia R. Martin, et al. "Polygenic scores in biomedical research." *Nat Rev Genet* 23 (2022): 524-532.
2. Choi, Shing Wan, Timothy Shin-Heng Mak and Paul F. O'Reilly. "Tutorial: A guide to performing polygenic risk score analyses." *Nat Protoc* 15 (2020): 2759-2772.
3. Kurniansyah, Nuzulul, Matthew O. Goodman, Tanika N. Kelly and Tali Elfassy, et al. "A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood." *Nature communications* 13 (2022): 3549.
4. Wojcik, Genevieve L., Mariaelisa Graff, Katherine K. Nishimura and Ran Tao, et al. "Genetic analyses of diverse populations improves discovery for complex traits." *Nature* 570 (2019): 514-518.
5. Ge, Tian, Marguerite R. Irvin, Amit Patki and Vinodh Srinivasasainagendra, et al. "Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations." *Genome Med* 14 (2022): 70.

How to cite this article: Anthena, Akkari. "The Promise and Perils of Direct-to-Consumer Genetic Testing in Clinical Practice." *J Clin Med Genomics* 12 (2024): 301.